Welcome to our dedicated page for BRUKER SEC filings (Ticker: BRKRP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BRUKER's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BRUKER's regulatory disclosures and financial reporting.
BRUKER CORP executive Mark Munch, Executive Vice President and President of Bruker Nano Inc., reported a Form 4 transaction involving company common stock. On 2026-08-11, 1,619 shares of common stock were withheld by the company at $57.02 per share to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units. Following this tax-withholding disposition, Munch directly holds 123,347 shares of BRUKER CORP common stock.
BRUKER CORP executive vice president and CFO Gerald N. Herman reported a Code F transaction involving 1,410 shares of common stock on 2026-08-11. According to the company’s disclosure, these shares were withheld to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units, rather than sold in an open-market transaction. Following this tax-withholding disposition, Herman’s directly held ownership stands at 98,284 shares of BRUKER CORP common stock.
BRUKER CORP President & CEO Frank H. Laukien reported a Form 4 reflecting a code F transaction in the company’s common stock. On 2026-08-11, 4,838 shares were withheld by the company at $57.02 per share to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units. After this withholding, Laukien directly holds 38,482,340 common shares. The filing also lists various indirect holdings for family members, including 336,607 shares held indirectly “By Daughter.”
BRUKER CORP executive Mark Munch, Executive VP and President of Bruker Nano Inc., reported two Form 4 transactions involving Common Stock coded "F". On 2026-08-10, 1,573 shares were withheld at $56.32 per share, and on 2026-08-09, 1,904 shares were withheld at $53.41 per share. According to the footnote, these 3,477 shares were withheld by the company to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units, rather than discretionary market sales.
BRUKER CORP executive Gerald N. Herman, Executive Vice President and CFO, reported two transactions in company common stock. On August 9, 2026, and August 10, 2026, a total of 2,889 shares were withheld by the company at prices of $53.41 and $56.32 per share, respectively. According to the disclosure, these shares were withheld solely to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units, rather than representing open-market sales.
BRUKER CORP President & CEO Frank H. Laukien reported two Form 4 transactions involving common stock used to cover taxes on equity compensation. On 2026-08-10, 4,564 shares were withheld at $56.32 per share, and on 2026-08-09, 2,361 shares were withheld at $53.41 per share. A footnote states these shares were withheld by the company to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units, rather than sold in open-market trades. The filing also lists several indirect ownership positions held through or for family members, including 336,607 shares held indirectly by a daughter after the reported date.
FMR LLC and Abigail P. Johnson report significant ownership of BRUKER CORP common stock. FMR LLC is listed with 23,296,465.55 shares beneficially owned, representing 15.0% of the class. FMR LLC has 17,974,598.38 shares with sole voting power and 23,296,465.55 shares with sole dispositive power, with no shared voting or dispositive power reported.
Abigail P. Johnson is also reported as a beneficial owner of 23,296,465.55 shares, equal to 15.0% of the class, with sole dispositive power and no voting or shared powers listed. One or more other persons have rights to dividends or sale proceeds tied to these shares, but no single such person holds more than five percent of BRUKER CORP’s outstanding common stock.
Bruker Corporation reported Q2 2026 revenue of $838.5 million, up from $797.4 million, with growth across BSI CALID, BSI NANO, and BEST. Gross profit rose to $416.0 million, but a $134.9 million goodwill impairment and other charges drove a consolidated operating loss of $65.3 million. After interest and other income of $24.6 million, taxes, and $10.9 million of preferred dividends, net loss attributable to common shareholders was $62.9 million, or $(0.41) per share, versus $0.05 earnings a year earlier.
For the first half of 2026, revenue was $1,661.9 million and net loss to common shareholders was $59.4 million. Bruker deployed $81.1 million of consideration (net of cash acquired) on acquisitions, including the remaining 60% of Tofwerk, adding goodwill of $35.4 million and identifiable intangibles (technology $42.7 million, customer relationships $3.5 million, tradename $1.6 million). Total goodwill decreased to $1,429.8 million after impairments of $98.4 million for the CST reporting unit and $36.5 million for the BSB reporting unit. Operating cash flow was a $6.2 million use, compared with $62.5 million use a year earlier; cash, cash equivalents and restricted cash were $189.1 million, and long-term debt was $1,814.7 million. Remaining performance obligations reached $2,775.6 million, and a post‑June 30 reorganization into BIOS, BMID, BSI NANO, and BEST will trigger an interim goodwill impairment analysis in the third quarter of 2026.
Bruker Corporation reported Q2 2026 revenue of $838.5 million, up 5.2% year over year, with organic growth of 2.8% and double‑digit organic bookings growth in its Scientific Instruments segment. BEST revenue rose 11.9% and BSI revenue increased 4.7%, reflecting strength in semiconductor, energy research, and biopharma markets, while U.S. academic demand remained soft.
GAAP results swung to a loss as a non‑cash goodwill impairment charge of $134.9 million drove a GAAP operating loss of $65.3 million and a GAAP diluted loss per share of $(0.41), versus earnings of $0.05 a year earlier. On a non‑GAAP basis, operating income rose to $118.5 million with margin expanding to 14.1%, and non‑GAAP diluted EPS increased to $0.49 from $0.32. For the first half, revenue grew 3.9% to $1,661.9 million, while free cash flow remained negative.
Bruker updated its 2026 outlook only for currency and tax, now expecting revenue of $3.54 to $3.57 billion, implying 3% to 4% growth, and reaffirming non‑GAAP EPS guidance of $2.10 to $2.15, 15% to 17% above 2025, assuming a 27.5% effective non‑GAAP tax rate.
Bruker Corporation declared a quarterly cash dividend of $3.9844 per share on its 6.375% Mandatory Convertible Preferred Stock, Series A. The dividend was declared on July 30, 2026 and is payable on September 1, 2026 to shareholders of record at the close of business on August 15, 2026. This action applies specifically to the company’s outstanding Series A preferred shares and reflects the stated 6.375% dividend rate on that class of stock.